Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

LRMR

Larimar Therapeutics Inc

Last Close
Apr 18 • 01:31PM ET
6.42
Dollar change
-0.63
Percentage change
-8.90 		%
Held by: VTI VXF IWM IWN VTWO ITOT IWC AVSC VTWV DFAC Scroll to Statements
IndexRUT P/E- EPS (ttm)-0.84 Insider Own41.05% Shs Outstand43.91M Perf Week-11.05%
Market Cap409.76M Forward P/E- EPS next Y-1.90 Insider Trans19.63% Shs Float37.61M Perf Month-25.23%
Income-36.95M PEG- EPS next Q-0.24 Inst Own39.02% Short Float8.49% Perf Quarter47.98%
Sales0.00M P/S- EPS this Y-49.35% Inst Trans72.24% Short Ratio5.10 Perf Half Y104.54%
Book/sh1.86 P/B3.45 EPS next Y-51.69% ROA-33.24% Short Interest3.19M Perf Year36.65%
Cash/sh1.36 P/C4.72 EPS next 5Y- ROE-38.36% 52W Range2.18 - 13.68 Perf YTD41.15%
Dividend Est.- P/FCF- EPS past 5Y48.33% ROI-42.75% 52W High-53.05% Beta0.95
Dividend TTM- Quick Ratio9.49 Sales past 5Y0.00% Gross Margin- 52W Low194.61% ATR (14)0.60
Dividend Ex-Date- Current Ratio9.49 EPS Y/Y TTM45.68% Oper. Margin0.00% RSI (14)33.99 Volatility5.66% 7.05%
Employees42 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price22.40
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q-37.82% Payout- Rel Volume0.54 Prev Close7.05
Sales Surprise- EPS Surprise-20.82% Sales Q/Q- EarningsMar 14 AMC Avg Volume625.74K Price6.42
SMA20-13.75% SMA50-29.02% SMA20025.91% Trades Volume217,007 Change-8.90%
Date Action Analyst Rating Change Price Target Change
Apr-03-24Initiated Leerink Partners Outperform $25
Nov-17-23Upgrade Citigroup Neutral → Buy $4.50
Oct-19-22Initiated Guggenheim Buy $12
Feb-15-22Downgrade William Blair Outperform → Mkt Perform
Feb-10-21Initiated JMP Securities Mkt Outperform
Feb-01-21Initiated William Blair Outperform $29
Mar-20-24 01:32PM
Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
(Insider Monkey)
Mar-14-24 09:53PM
LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023
(InvestorPlace) -6.51%
05:32PM
Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results
(GuruFocus.com)
04:05PM
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
(GlobeNewswire)
Mar-11-24 04:05PM
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia
(GlobeNewswire) -15.39%
04:05PM Loading…
Mar-06-24 04:05PM
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
(GlobeNewswire)
Feb-20-24 01:47PM
Hedge Fund and Insider Trading News: Bill Ackman, George Soros, Arkhouse Management, TYR Capital, Borea Asset Management, Larimar Therapeutics, Inc. (LRMR), and More
(Insider Monkey) -5.63%
Feb-19-24 01:48PM
Hedge Fund and Insider Trading News: Bill Ackman, David Tepper, Mark Yusko, Elliott Management, Conestoga Capital Advisors, Larimar Therapeutics Inc (LRMR), Agree Realty Corporation (ADC), and More
(Insider Monkey)
Feb-16-24 04:20PM
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
(GlobeNewswire)
Feb-14-24 06:15AM
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
(GlobeNewswire) +36.84%
Feb-13-24 04:18PM
Larimar Therapeutics Announces Proposed Underwritten Public Offering
(GlobeNewswire) +11.62%
Feb-12-24 07:00AM
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia
(GlobeNewswire)
Nov-14-23 07:00AM
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
(GlobeNewswire) +7.11%
Nov-01-23 04:05PM
Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference
(GlobeNewswire)
Oct-03-23 04:05PM
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
(GlobeNewswire) -5.83%
04:05PM Loading…
Aug-31-23 04:05PM
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
(GlobeNewswire)
Aug-10-23 07:00AM
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
(GlobeNewswire)
Aug-07-23 09:22AM
Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2m
(Simply Wall St.) -7.19%
Jul-25-23 09:59AM
These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts
(TipRanks) +7.67%
07:00AM
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial
(GlobeNewswire)
Jul-17-23 04:05PM
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
(GlobeNewswire)
Jun-21-23 04:05PM
Larimar Therapeutics Set to Join Russell 3000® Index
(GlobeNewswire)
May-15-23 07:00AM
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trials 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreichs Ataxia and First Quarter 2023 Financial Results
(GlobeNewswire) -29.05%
Mar-28-23 04:05PM
Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
(GlobeNewswire)
Mar-14-23 07:00AM
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
(GlobeNewswire)
Feb-07-23 04:05PM
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
(GlobeNewswire) +6.52%
Nov-21-22 04:05PM
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
(GlobeNewswire)
Nov-10-22 07:00AM
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
(GlobeNewswire)
Nov-07-22 04:05PM
Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day
(GlobeNewswire)
Oct-20-22 08:00AM
Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
(GlobeNewswire)
04:05PM Loading…
Oct-19-22 04:05PM
Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research
(GlobeNewswire)
Sep-16-22 01:00PM
Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares
(GlobeNewswire) -5.04%
Sep-14-22 07:04AM
Larimar Therapeutics Announces $70 Million Underwritten Offering
(GlobeNewswire) +15.56%
07:01AM
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreichs Ataxia Patients
(GlobeNewswire)
Aug-11-22 04:05PM
Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results
(GlobeNewswire)
Jul-28-22 04:05PM
Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders
(GlobeNewswire)
Jun-28-22 08:00AM
Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts
(GlobeNewswire)
06:05AM
We're Keeping An Eye On Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Rate
(Simply Wall St.)
Jun-02-22 08:00AM
Larimar Therapeutics Announces Upcoming Scientific Conference Presentations
(GlobeNewswire)
May-19-22 08:00AM
Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinsons Disease and Movement Disorders Congress
(GlobeNewswire)
May-12-22 07:00AM
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
(GlobeNewswire) -7.91%
Apr-29-22 06:27AM
Despite recent gains, Larimar Therapeutics, Inc. (NASDAQ:LRMR) insiders are still down US$273k after purchasing last year
(Simply Wall St.) -5.84%
Apr-13-22 10:40AM
Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)
(Zacks)
Mar-25-22 07:00AM
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
(GlobeNewswire)
Feb-16-22 11:57AM
Larimar Therapeutics' stock plunges on FDA decision; could implement cost-cutting measures
(American City Business Journals)
Feb-14-22 04:01PM
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
(GlobeNewswire)
Jan-19-22 06:53AM
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
(Simply Wall St.)
Nov-22-21 07:00AM
Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
(GlobeNewswire)
Nov-20-21 08:40AM
In spite of Larimar Therapeutics, Inc.'s recent pullback, insiders still gained about US$85k after buying earlier this year.
(Simply Wall St.)
Nov-15-21 07:00AM
Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference
(GlobeNewswire)
Nov-12-21 07:00AM
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
(GlobeNewswire) -8.72%
Sep-16-21 08:00AM
Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event
(GlobeNewswire) -7.48%
Sep-02-21 04:01PM
Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
(GlobeNewswire) +5.81%
Aug-22-21 10:12AM
What You Need To Know About Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) Investor Composition
(Simply Wall St.)
Aug-19-21 07:00AM
Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress
(GlobeNewswire)
Aug-12-21 07:00AM
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
(GlobeNewswire) +17.79%
Aug-09-21 08:48AM
Why Larimar (LRMR) Might Surprise This Earnings Season
(Zacks)
Jul-23-21 12:00PM
Larimar (LRMR) Upgraded to Buy: Here's Why
(Zacks)
Jul-08-21 04:01PM
Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021
(GlobeNewswire)
Jun-11-21 07:00AM
Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference
(GlobeNewswire)
Jun-05-21 07:55PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
(Newsfile)
Jun-02-21 10:56PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
(GlobeNewswire)
Jun-01-21 04:55AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
(PR Newswire)
May-29-21 10:59PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
(Newsfile)
May-25-21 05:41PM
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
(GlobeNewswire) -10.59%
May-21-21 09:18AM
Larimar Therapeutics Announces $95 Million Private Placement Financing
(GlobeNewswire) +11.17%
May-20-21 04:31PM
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreichs Ataxia
(GlobeNewswire) +10.17%
May-11-21 07:00AM
Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreichs Ataxia
(GlobeNewswire) -36.28%
May-10-21 04:05PM
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
(GlobeNewswire) -5.34%
Mar-04-21 07:00AM
Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
(GlobeNewswire)
Mar-01-21 03:54AM
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation
(Simply Wall St.)
Feb-18-21 04:01PM
Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference
(GlobeNewswire)
Dec-16-20 07:23PM
Is LRMR A Good Stock To Buy Now?
(Insider Monkey)
Dec-15-20 08:00AM
Larimar Therapeutics Added to NASDAQ Biotechnology Index
(GlobeNewswire)
Dec-08-20 07:30AM
Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreichs Ataxia Patients and Provides Program Update
(GlobeNewswire)
Nov-13-20 08:00AM
Larimar Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire) +16.58%
Nov-10-20 08:00AM
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
(GlobeNewswire) -6.12%
Oct-14-20 10:18PM
Hedge Funds Are Betting On Larimar Therapeutics, Inc. (LRMR)
(Insider Monkey)
Oct-13-20 08:00AM
Larimar Therapeutics Announces Formation of Scientific Advisory Board
(GlobeNewswire) +22.55%
Sep-21-20 09:58AM
Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
(GlobeNewswire) -6.19%
Sep-10-20 08:00AM
Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
(GlobeNewswire) +7.50%
Sep-01-20 12:47PM
What Is The Ownership Structure Like For Larimar Therapeutics, Inc. (NASDAQ:LRMR)?
(Simply Wall St.)
Aug-11-20 07:00AM
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
(GlobeNewswire) +9.43%
Aug-04-20 08:00AM
Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
(GlobeNewswire)
Jul-28-20 08:00AM
Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreichs Ataxia
(GlobeNewswire)
Jul-20-20 04:15PM
Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreichs Ataxia
(GlobeNewswire)
May-29-20 04:05PM
Larimar Therapeutics to Present at Jefferies Virtual Healthcare Conference
(GlobeNewswire)
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James EDirectorFeb 16 '24Buy8.744,290,61737,499,9936,151,406Feb 16 02:37 PM
THOMAS FRANK EDirectorFeb 14 '24Buy11.002,00022,0002,000Feb 15 04:21 PM
Shankar GopiChief Development OfficerDec 07 '23Buy3.735,00018,6625,000Dec 08 04:08 PM
Celano MichaelChief Financial OfficerMay 17 '23Buy3.735,00018,632112,746May 18 02:13 PM
BEN-MAIMON CAROLEPresident and CEOMay 17 '23Buy3.715,00018,525266,829May 18 02:13 PM
Truitt JosephDirectorMay 17 '23Buy3.732,75010,2582,750May 18 02:12 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.